Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 7Stomach Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neoplasms 2Rectal Neoplasms 1Rectal Diseases 1Intestinal Neoplasms 1Intestinal Diseases 1HER2+ Metastatic Breast Cancer (MBC) 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Colonic Diseases 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 25Cisplatin 9Paclitaxel 6Fluorouracil 5Carboplatin 4Saline Solution 3Capecitabine 3Bevacizumab 3Oxaliplatin 2Gemcitabine 2Docetaxel 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2lenvatinib 1Trastuzumab 1S 1 (combination) 1Irinotecan 1IFL protocol 1Glucose 1Doxorubicin 1Brentuximab Vedotin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Capecitabine × Clear all
NCT03675737 2026-02-27

KEYNOTE-859

Merck Sharp & Dohme LLC

Phase 3 Completed
1,579 enrolled 31 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Merck Sharp & Dohme LLC

Phase 3 Completed
738 enrolled 22 charts 3 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

Merck Sharp & Dohme LLC

Phase 2 Completed
318 enrolled 24 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡